Gustavo Perez Fernandez, president of Leica Biosystems, indicated that the acquisition serves as a strategic bridge toward modernizing laboratory environments. The integration of StatLab’s products is designed to provide the consistency and quality control required for advanced digital pathology adoption. Leica, which operates as part of the broader Danaher science and technology group alongside entities like Cytiva and Beckman Coulter, will absorb StatLab from its current owners, Linden Capital Partners and Audax Private Equity.
In section Market Quotes
Leica Biosystems to Acquire StatLab Medical Products
Leica Biosystems is set to acquire StatLab Medical Products, a move aimed at bolstering the diagnostic capabilities of the Danaher Corp. subsidiary. By integrating StatLab’s anatomical pathology portfolio, the company intends to establish the standardized laboratory workflows necessary to deploy artificial intelligence for large-scale cancer diagnostics.
The companies have not disclosed the financial details of the agreement. The transaction is currently slated to finalize by the end of 2026, marking a shift in Leica's efforts to automate and scale cancer detection technologies across its global laboratory network.
Comments (0)
No comments yet. Be the first!